Roche Diagnostics had sales of CHF 12.88 billion in 2018. For the fourth quarter, diagnostics sales totaled CHF 3.5 billion, up 10 percent year over year.
A molecular assay used in combination with patient-collected samples had similar accuracy to testing with clinician collected samples.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.
Called CerMark, the test is aimed at women in resource-constrained settings and will measure proteins linked to HPV infection and cervical disease progression.
The a single-tube, multiplex real-time PCR-based MeltPro High Risk HPV test identifies 14 high-risk genotypes of human papillomavirus and was previously CE marked.
The firm said the decline in Q4 revenues was due to an account loss as well as lower insurance reimbursement and shifts away from high-value genetic testing.
The so-called enVision HPV test performed well in a comparison to Roche's Cobas HPV assay, and the Singapore researchers are considering other test applications.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.